Skip to main content
Trending storyContinuously updated

Nouscom raises €120M Series D for NOUS-209 cancer vaccine trial

2 reports2 report sources2 hours agoUpdate

Get up to speed on this story

AI Summary

Basel-based Nouscom closed an oversubscribed €120 million ($135 million) Series D to fund NOUS-209, its investigational off-the-shelf neoantigen cancer immunotherapy. M Ventures and Revelation Partners co-led the round, joined by new investors Angelini Ventures, the EIB and Neva SGR (Intesa Sanpaolo Group). The proceeds are earmarked for a single global, registration-enabling trial of NOUS-209 in Lynch Syndrome carriers, aimed at cancer interception. The FDA granted the candidate Fast Track designation, which Tech Funding News dates to June 1, 2026.

AI-generated from reports · 2 hours agoUpdate

Latest updatesOct 19 18:21
Nouscom raises $135M Series D to test cancer prevention vaccine NOUS-209

Report timeline

Follow the reports to understand different sides of the story.

Oct 19
  1. Tech Funding NewsTop Deals
    Nouscom raises $135M Series D to test cancer prevention vaccine NOUS-209

    Nouscom raised a $135M Series D co-led by M Ventures and Revelation Partners to fund a global registration-enabling trial of NOUS-209.

  2. EU-Startups FundingTop Deals
    Nouscom raises €120M Series D to advance off-the-shelf cancer immunotherapy

    Basel-based Nouscom closed an oversubscribed €120 million ($135 million) Series D co-led by M Ventures and Revelation Partners.

Trend for this story

Comparable range current
10
Comparable range peak
10Oct 19 19:00
Change in the last 24 hours
–

Trends only compare the same entities observed consistently and completely, so the scope may be smaller than the current trending statistics. Move the pointer or click the chart to view hourly trending; use the left and right arrow keys on a keyboard to switch.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing